Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder by Fulton F. Velez, Daniel C. Malone

Get full text

Alzheimer's disease medication and risk of all‐cause mortality and all‐cause hospitalization: A retrospective cohort study by Sandipan Bhattacharjee, Asad E. Patanwala, Wei‐Hsuan Lo‐Ciganic, Daniel C. Malone, Jeannie K. Lee, Shannon M. Knapp, Terri Warholak, William J. Burke

Get full text

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients by Daniel C. Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Omar Dabbous

Get full text

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States by Alexa C. Klimchak, Lauren E. Sedita, Louise R. Rodino-Klapac, Jerry R. Mendell, Craig M. McDonald, Katherine L. Gooch, Daniel C. Malone

Get full text

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and... by Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous

Get full text

Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) by Charles E Leonard, Ainhoa Gomez-Lumbreras, Daniel C Malone, Kathleen M Andersen, G Caleb Alexander, Olga V Kravchenko, Richard D Boyce, Paul T Kocis, Lorenzo Villa Zapata, Malinda Tan, Hemalkumar Mehta

Get full text